This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cancer Tissue Diagnostics Market

New Wave of Innovation in the Cancer Tissue Diagnostics Market: An Analysis by FMI

Cancer Tissue Diagnostics Market by Test Type & region - Forecast 2022 - 2032

Cancer Tissue Diagnostics Market Outlook (2022-2032)

[324 Pages Report] The global cancer tissue diagnostics market is expected to reach a market valuation of US$ 5.3 Billion by the year 2022, accelerating with a moderate CAGR of 6.6% by 2022-2032. Cancer tissue diagnostics market size is anticipated to be valued at about US$ 10.04 Billion by 2032 end.

The biological context of cancer cells may be captured by tissue diagnostics, making them one of the most reliable methods for making a cancer diagnosis and treatment plan. High demand and promising future growth in the cancer tissue diagnostics market might be attributed to the rising cancer rate.

Increased adoption of automated cancer diagnosis methods and technologies by research institutes facilitates quicker tumor diagnosis. The West Clinic Cancer Center, for instance, teamed with F. Hoffmann-La Roche Ltd. in September 2019 to use the BenchMark ULTRA Automated Advanced Staining System, developed by Roche, to enhance patient cancer treatment. In situ hybridization and immunohistochemistry testing can be performed using this technology for a quicker cancer tissue diagnostics.

Several factors, including the rising incidence of cancers of all kinds, the growing interest in preventative health care, the expansion of digital pathology's applications, the intensification of cancer awareness campaigns, the development of more effective diagnostic and monitoring tools, and the general improvement in diagnostic accuracy, bode well for the global cancer tissue diagnostics market.

While the global cancer tissue diagnostics market is expected to expand during the forecast period, its expansion is expected to be stymied by factors such as the high price of diagnostic procedures and a lack of experienced and professional workers in the industry.

Attributes

Value

Cancer Tissue Diagnostics Market Size (2022)

US$ 5.3 Billion

Cancer Tissue Diagnostics Market Projected Size (2032)

US$ 10.04 Billion

Cancer Tissue Diagnostics Market Value CAGR (2022-2032)

6.6%

Customize this Report

Let us know your requirement to get
100% FREE customization

What are Some Factors Shaping the future of Cancer Tissue Diagnostics Market?

Cancer diagnostics research is expected to drive the demand.

The rise in cancer incidence has boosted cancer tissue diagnostics research and development. According to the WHO, the global cancer burden grew in 2020, with 18 million new cases and 9.6 million deaths (WHO). Increased academic-commercial partnerships to further cancer research is likely to increase the global cancer tissue diagnostics market.

The University of Sheffield in the UK signed a collaboration agreement with Zilico Ltd in June 2020 to develop a painless, fast, and non-invasive method of diagnosing oral cancer using EIS technology.

Swiss life-sciences firm Lunaphore Technologies SA develops next-generation cancer research equipment. In the same month, Epredia, a global leader in cancer diagnostics and tissue diagnostics, signed a strategic distribution deal with the firm. Fast Fluidic Exchange microfluidic technology is forecasted to be integrated into tissue diagnostic instruments by industry leader Lunaphore to deliver chemicals to tissue samples for quick IHC and immunofluorescence assays (IF).

Scarcity Of Qualified Workers

Histology laboratories are vital to the accuracy, safety, and speed of sickness diagnosis. Histology is needed to understand illness causes and how therapies operate. Cancer rates increase the requirement for clinical histology services. 80% of cancer diagnostics involve histology. These facilities are understaffed.

According to inside lab 2020, only 3% of UK diagnostic labs had enough staff to perform diagnostic and regular tasks including reporting. Germany has the lowest proportion of pathologists to practising physicians in Europe, the US, and Canada. Germany's ratio is 1:200, while the US and Canada both have 1:70. PubMed 2020 as many histologists retire, few are entering the field. Histology labs are struggling to process more samples with fewer workers. This could limit cancer tissue diagnostics market growth.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Adjacent Cancer Tissue Diagnostics Market

Cancer Tissue Diagnostics Market:

Attributes

Cancer Tissue Diagnostics Market

CAGR (2022 to 2032)

6.6%

Market Value (2022)

US$ 5.3 Billion

Growth Factor

An increasing number of cases of cancer is expected to drive the cancer tissue diagnostics market.

Future Opportunities

Increased emphasis being placed on individualized medical cancer treatment which is opening new horizons in the cancer tissue diagnostics market.

Market Trends

Lack of available and skilled workers is expected to retrain the growth of the cancer tissue diagnostics market.

Molecular Diagnostics Market:

Attributes

Molecular Diagnostics Market

CAGR (2022 to 2032)

5.4%

Market Value (2022)

US$ 23.2 Billion

Growth Factor

Both increasing technological capabilities in molecular diagnostics and rising awareness of the importance of early disease diagnosis in developing countries are propelling the market forward.

Future Opportunities

Market leaders in molecular diagnostics can anticipate having expansion prospects in developing economies including India, China, South Korea, Brazil, Turkey, Russia, and South Africa.

Market Trends

A major barrier limiting the expansion of the molecular diagnostics business is inadequate reimbursements.

In vitro Diagnostics Market:

Attributes

In vitro Diagnostics Market

CAGR (2022 to 2032)

2.9%

Market Value (2022)

US$ 98.2 Billion

Growth Factor

The need is anticipated to be driven by the transition from centralised to point-of-care testing.

Future Opportunities

Potential growth possibilities for market players are anticipated to emerge from the development of disease-specific markers and diagnostics in the future years.

Market Trends

The in vitro diagnostics market is likely to slow down in the coming years due to the adverse reimbursement scenario.

The rising cancer cell rate has resulted in a surge in interest in oncology diagnostics. This has prompted government agencies, healthcare providers, and institutions to create facilities for effective illness diagnosis and treatment. Because of this, the cancer tissue diagnostics market is growing rapidly. Roche's uPath HER2 (4B5) and uPath HER2 Dual ISH digital pathology image analyzers are algorithms for precise patient diagnosis in breast cancer, and they were released in 2021. This is positively changing the cancer tissue diagnostics market outlook.

Country-Wise Analysis of the Cancer Tissue Diagnostics Market

United States

  • The United States has dominated the North American cancer tissue diagnostics market. Stakeholders in the U.S. business are expanding in response to an uptick in cancer diagnoses and improved diagnostic tools.
  • As per the cancer tissue diagnostics market report, the average probability of a woman in the United States acquiring breast cancer in her lifetime is about 13%. An estimated 234,030 new instances of lung cancer were discovered in 2018, and there are already 541,000 Americans who have been diagnosed with lung cancer at some time in their lives.
  • These findings show the vast potential for development and expansion in the U.S. cancer tissue diagnostics market.

Japan

  • Since the last decade, cancer tissue diagnostics in Japan has become an attractive market. The sophisticated diagnostics sector and the rising need to detect malignancies of the lung, breast, prostate, and elsewhere are driving this cancer tissue diagnostics market expansion in Japan.
  • According to the "Global Cancer Data by Country" report by the World Cancer Research Fund, the most frequent malignancies in Japan are breast cancer, lung cancer, stomach cancer, colorectum cancer, and prostate cancer, with an age-standardized rate of 248.0 cases per 100,000 people. Due to the rising need for cancer tissue diagnostic solutions, businesses in the cancer tissue diagnostics market should expect increased profits in the future.

China

  • Supply companies in the cancer tissue diagnostics industry are taking notice of China because of its advanced medical and diagnostic sectors. The rising number of cancer cases in China is helping to fuel the cancer tissue diagnostics market expansion.
  • About 4,285,033 new instances of cancer were identified in China in 20202, including 2,366,010 male and 1,919,023 female cases. According to the data presented, the crude and age-standardized death rates for men were 201.3 and 130.1 per 100,000, respectively. These projections indicate that China is likely to continue to be a focal point for the cancer tissue diagnostics industry.

Germany

  • The cancer tissue diagnostics market in Western Europe is currently led by Germany and is expected to be led by Germany for the foreseeable future. Germany's highly established manufacturing hubs and rising awareness of the need of early cancer detection test are driving the expansion.
  • The World Cancer Research Fund reports that the age-adjusted rate of cancer in Germany is 313.1 cases per 100,000 people. This number includes cases of lung, breast, and prostate cancers. These numbers highlight expanding markets for German makers of diagnostic tools for cancer tissue.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competitive Landscape for the Cancer Tissue Diagnostics Market

Top companies in the cancer tissue diagnostics industry are paying more attention to the growing demand for their products in digital pathology. This is expected to prompt strategic partnerships in the global cancer tissue diagnostics market between technology providers and digital pathology platforms soon.

In July of 2020, for instance, Koninklijke Philips N.V., a Dutch multinational conglomerate corporation and one of the world's largest electronics companies with a focus on health technology, announced that it had partnered with Proscia Inc., a Philadelphia-based provider of digital pathology platform, to establish an open ecosystem for diagnostic laboratories to boost and scale their operations on the platform of digital pathologies.

Through this partnership, Philips' iSyntax image format is expected to be integrated with the Philips Pathology SDK software toolset and Proscia's suite of AI modules will be made available on the company's Concentriq digital pathology platform.

The Swiss pharmaceutical and diagnostics conglomerate F. Hoffmann-La Roche AG has announced the CE-IVD launch of its cutting-edge, fully automated digital pathology platform uPath PD-L1 (SP263) for non-small cell lung cancer research in June 2020. (NSCLC).

The firm stated that the decision was motivated by a desire to increase reliability and uniformity in diagnostic laboratories by implementing AI-powered image analysis capabilities.

Global Cancer Tissue Diagnostics Market Key Players

  • Abbott Laboratories
  • F.Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Ventana Medical Systems, Inc.
  • Bio Rad Laboratories Inc.
  • Enzo Life Sciences, Inc.
  • Abcam plc.
  • BioGenex
  • Cell Signalling Technology, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.
  • Bio SB
  • Cancer Genetics Inc.
  • Danaher Corporation
  • ROSETTA GENOMICS
  • Nanoprobes, Inc.
  • Creative-Biolabs
  • Enzo Life Sciences, Inc.
  • Sigma-Aldrich Co., LLC

3 AI Innovations Changing Cancer Diagnosis and Treatment

Cancer remains one of the world's deadliest diseases, despite significant progress in cancer treatment and detection over the previous several decades. The finest weapons doctors have against this disease are identification and treatment administered early on. However, difficulties, such as high false-positive rates and difficulty forecasting cancer treatment success, can impede the process.

Now, healthcare experts and medical researchers are discovering methods to use the latest advancements from outside of medicine - like artificial intelligence - to the diagnosis and treatment of cancer. Here are just three examples of such cutting-edge equipment.

Estimating the Likelihood of Successful Immunotherapy

Immunotherapy is a novel approach to cancer treatment that makes use of medications to stimulate the immune system to better combat cancer cells. When compared to conventional therapies like chemotherapy and radiation, this one often has less negative side effects and better success rates. Yet not every patient has the same experience, and the efficacy of immunotherapy cannot be predicted.

This could potentially alter with the introduction of a new artificial intelligence technology. Patients who are likely to benefit from immunotherapy could be selected using an algorithm in conjunction with routine CT scans. This would expedite their cancer treatment while also allowing doctors to treat other patients who are waiting for alternatives like chemotherapy.

Mass spectrometry imaging: Routine 3D tissue analysis is becoming a reality

The use of mass spectrometry for imaging purposes is a significant technological advance in spectral research. A 3D chemical map can be created by examining the spectra of individual molecules in tissue. This method has many potential applications, including the detection of hypoxic tumour sites, the characterization of spheroids, and the evaluation of alterations in the tumour microenvironment (TME). Recent technological advancements have made it possible to take these kinds of measurements at a high throughput, casting doubt on the feasibility of routine 3D tumour investigations.

Optimizing results from next-generation sequencing through careful tissue handling

Improvements in dependability and data management are largely responsible for the growth of next-generation sequencing in the therapeutic setting. The past decade has seen NGS facilitate the discovery of novel genomic variants and driving mutations, clarifying new targets for medication development. Researchers have also been able to pinpoint more accurate predictive and prognostic biomarkers for therapy thanks to NGS.

As part of its mission to promote improved diagnosis and cancer treatment decisions, Genomics England launched the 100,000 Genomes Initiative in 2012, making it the largest sequencing research project in the world. The research is also expected to improve techniques for 'genome-friendly' tissue processing.

Cancer Tissue Diagnostics Market by Segmentation

By Test Type:

  • Immunohistochemical (IHC) Test
    • Breast Cancer
    • Stomach (Gastric) Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • In Situ Hybridization (ISH) Test
    • Breast cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Bladder Cancer
    • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

The cancer tissue diagnostics market is expected to grow at 6.6% CAGR over 2022-2032.

The cancer tissue diagnostics market is estimated to be around US$ 5.3 Billion in 2022.

The cancer tissue diagnostics market is anticipated to reach a valuation of US$ 10.04 Billion by 2032.

Cancer is one of several deadly diseases that have seen a dramatic increase in the United States, prompting a surge in cancer-related research and diagnostics across the continent of North America.

Table of Content

1. Executive Summary

2. Cancer Tissue Diagnostics Introduction

    2.1. Cancer Tissue Diagnostics Definition

    2.2. Cancer Tissue Diagnostics Taxonomy

3. Cancer Tissue Diagnostics Analysis Scenario

    3.1. Cancer Tissue Diagnostics Size (US$ Mn) and Forecast

        3.1.1. Market Size and Y-o-Y Growth

        3.1.2. Absolute $ Opportunity

4. Cancer Tissue Diagnostics Analysis Scenario

    4.1. Macro-economic Factors

    4.2. Drivers

        4.2.1. Supply Side

        4.2.2. Demand Side

    4.3. Restraints

    4.4. Opportunity

    4.5. Trends

    4.6. Cancer Epidemiology

    4.7. Cancer Tissue Diagnostics Regulatory and Reimbursement Scenario

    4.8. Porter’s Analysis

5. Global Cancer Tissue Diagnostics Analysis and Forecast, By Test Type

    5.1. Introduction

        5.1.1. Basis Point Share (BPS) Analysis By Test Type

        5.1.2. Y-o-Y Growth Projections By Test Type

    5.2. Market Size (US$ Mn) Forecast By Test Type

        5.2.1. Immunohistochemical (IHC) Test

            5.2.1.1. Breast Cancer

            5.2.1.2. Stomach (gastric) Cancer

            5.2.1.3. Colorectal Cancer

            5.2.1.4. Prostate Cancer

            5.2.1.5. Others

        5.2.2. In situ hybridization (ISH) Test

            5.2.2.1. Breast Cancer

            5.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            5.2.2.3. Bladder Cancer

            5.2.2.4. Others

    5.3. Market Attractiveness Analysis By Test Type

6. Global Cancer Tissue Diagnostics Analysis and Forecast, By Region

    6.1. Introduction

        6.1.1. Basis Point Share (BPS) Analysis By Region

        6.1.2. Y-o-Y Growth Projections By Region

    6.2. Market Size (US$ Mn) Forecast By Region

        6.2.1. North America

        6.2.2. Western Europe

        6.2.3. Asia Pacific Excl. Japan (APEJ)

        6.2.4. Japan

        6.2.5. Latin America

        6.2.6. Eastern Europe

        6.2.7. Middle East and Africa (MEA)

    6.3. Market Attractiveness Analysis By Region

7. North America Cancer Tissue Diagnostics Analysis and Forecast

    7.1. Introduction

        7.1.1. Basis Point Share (BPS) Analysis

        7.1.2. Y-o-Y Growth Projections

    7.2. Market Size (US$ Mn) Forecast By Test Type

        7.2.1. Immunohistochemical (IHC) Test

            7.2.1.1. Breast Cancer

            7.2.1.2. Stomach (gastric) Cancer

            7.2.1.3. Colorectal Cancer

            7.2.1.4. Prostate Cancer

            7.2.1.5. Others

        7.2.2. In situ hybridization (ISH) Test

            7.2.2.1. Breast Cancer

            7.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            7.2.2.3. Bladder Cancer

            7.2.2.4. Others

    7.3. Market Value Forecast By Country, 2022-2032

        7.3.1. United States

        7.3.2. Canada

    7.4. Market Attractiveness Analysis

        7.4.1. By Test Type

        7.4.2. By Country

8. Latin America Cancer Tissue Diagnostics Analysis and Forecast

    8.1. Introduction

        8.1.1. Basis Point Share (BPS) Analysis

        8.1.2. Y-o-Y Growth Projections

    8.2. Market Size (US$ Mn) Forecast By Test Type

        8.2.1. Immunohistochemical (IHC) Test

            8.2.1.1. Breast Cancer

            8.2.1.2. Stomach (gastric) Cancer

            8.2.1.3. Colorectal Cancer

            8.2.1.4. Prostate Cancer

            8.2.1.5. Others

        8.2.2. In situ hybridization (ISH) Test

            8.2.2.1. Breast Cancer

            8.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            8.2.2.3. Bladder Cancer

            8.2.2.4. Others

    8.3. Market Value Forecast By Country, 2022-2032

        8.3.1. Brazil

        8.3.2. Mexico

        8.3.3. Rest of Latin America

    8.4. Market Attractiveness Analysis

        8.4.1. By Test Type

        8.4.2. By Country

9. Western Europe Cancer Tissue Diagnostics Analysis and Forecast

    9.1. Introduction

        9.1.1. Basis Point Share (BPS) Analysis

        9.1.2. Y-o-Y Growth Projections

    9.2. Market Size (US$ Mn) Forecast By Test Type

        9.2.1. Immunohistochemical (IHC) Test

            9.2.1.1. Breast Cancer

            9.2.1.2. Stomach (gastric) Cancer

            9.2.1.3. Colorectal Cancer

            9.2.1.4. Prostate Cancer

            9.2.1.5. Others

        9.2.2. In situ hybridization (ISH) Test

            9.2.2.1. Breast Cancer

            9.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            9.2.2.3. Bladder Cancer

            9.2.2.4. Others

    9.3. Market Value Forecast By Country, 2022-2032

        9.3.1. UK

        9.3.2. France

        9.3.3. Germany

        9.3.4. Spain

        9.3.5. Italy

        9.3.6. Rest of Western Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Test Type

        9.4.2. By Country

10. Eastern Europe Cancer Tissue Diagnostics Analysis and Forecast

    10.1. Introduction

        10.1.1. Basis Point Share (BPS) Analysis

        10.1.2. Y-o-Y Growth Projections

    10.2. Market Size (US$ Mn) Forecast By Test Type

        10.2.1. Immunohistochemical (IHC) Test

            10.2.1.1. Breast Cancer

            10.2.1.2. Stomach (gastric) Cancer

            10.2.1.3. Colorectal Cancer

            10.2.1.4. Prostate Cancer

            10.2.1.5. Others

        10.2.2. In situ hybridization (ISH) Test

            10.2.2.1. Breast Cancer

            10.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            10.2.2.3. Bladder Cancer

            10.2.2.4. Others

    10.3. Market Value Forecast By Country, 2022-2032

        10.3.1. Russia

        10.3.2. Poland

        10.3.3. Rest of Eastern Europe

    10.4. Market Attractiveness Analysis

        10.4.1. By Test Type

        10.4.2. By Country

11. Asia Pacific Excl. Japan (APEJ) Cancer Tissue Diagnostics Analysis and Forecast

    11.1. Introduction

        11.1.1. Basis Point Share (BPS) Analysis

        11.1.2. Y-o-Y Growth Projections

    11.2. Market Size (US$ Mn) Forecast By Test Type

        11.2.1. Immunohistochemical (IHC) Test

            11.2.1.1. Breast Cancer

            11.2.1.2. Stomach (gastric) Cancer

            11.2.1.3. Colorectal Cancer

            11.2.1.4. Prostate Cancer

            11.2.1.5. Others

        11.2.2. In situ hybridization (ISH) Test

            11.2.2.1. Breast Cancer

            11.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            11.2.2.3. Bladder Cancer

            11.2.2.4. Others

    11.3. Market Value Forecast By Country, 2022-2032

        11.3.1. China

        11.3.2. Australia

        11.3.3. India

        11.3.4. ASEAN

        11.3.5. Rest of APEJ

    11.4. Market Attractiveness Analysis

        11.4.1. By Test Type

        11.4.2. By Country

12. Japan Cancer Tissue Diagnostics Analysis and Forecast

    12.1. Introduction

        12.1.1. Basis Point Share (BPS) Analysis

        12.1.2. Y-o-Y Growth Projections

    12.2. Market Size (US$ Mn) Forecast By Test Type

        12.2.1. Immunohistochemical (IHC) Test

            12.2.1.1. Breast Cancer

            12.2.1.2. Stomach (gastric) Cancer

            12.2.1.3. Colorectal Cancer

            12.2.1.4. Prostate Cancer

            12.2.1.5. Others

        12.2.2. In situ hybridization (ISH) Test

            12.2.2.1. Breast Cancer

            12.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            12.2.2.3. Bladder Cancer

            12.2.2.4. Others

    12.3. Market Attractiveness Analysis

        12.3.1. By Test Type

13. MEA Cancer Tissue Diagnostics Analysis and Forecast

    13.1. Introduction

        13.1.1. Basis Point Share (BPS) Analysis

        13.1.2. Y-o-Y Growth Projections

    13.2. Market Size (US$ Mn) Forecast By Test Type

        13.2.1. Immunohistochemical (IHC) Test

            13.2.1.1. Breast Cancer

            13.2.1.2. Stomach (gastric) Cancer

            13.2.1.3. Colorectal Cancer

            13.2.1.4. Prostate Cancer

            13.2.1.5. Others

        13.2.2. In situ hybridization (ISH) Test

            13.2.2.1. Breast Cancer

            13.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

            13.2.2.3. Bladder Cancer

            13.2.2.4. Others

    13.3. Market Value Forecast By Country, 2022-2032

        13.3.1. GCC Countries

        13.3.2. South Africa

        13.3.3. Rest of MEA

    13.4. Market Attractiveness Analysis

        13.4.1. By Test Type

        13.4.2. By Country

14. Competition Landscape

    14.1. Competition Dashboard

    14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

        14.2.1. Abbott Laboratories

            14.2.1.1. Overview

            14.2.1.2. Financials

            14.2.1.3. Strategy

            14.2.1.4. Recent Developments

        14.2.2. F. Hoffmann-La Roche Ltd.

            14.2.2.1. Overview

            14.2.2.2. Financials

            14.2.2.3. Strategy

            14.2.2.4. Recent Developments

        14.2.3. Thermo Fisher Scientific Inc.

            14.2.3.1. Overview

            14.2.3.2. Financials

            14.2.3.3. Strategy

            14.2.3.4. Recent Developments

        14.2.4. Ventana Medical Systems, Inc

            14.2.4.1. Overview

            14.2.4.2. Financials

            14.2.4.3. Strategy

            14.2.4.4. Recent Developments

        14.2.5. Bio Rad Laboratories Inc.

            14.2.5.1. Overview

            14.2.5.2. Financials

            14.2.5.3. Strategy

            14.2.5.4. Recent Developments

        14.2.6. Enzo Life Sciences, Inc.

            14.2.6.1. Overview

            14.2.6.2. Financials

            14.2.6.3. Strategy

            14.2.6.4. Recent Developments

        14.2.7. Abcam plc.

            14.2.7.1. Overview

            14.2.7.2. Financials

            14.2.7.3. Strategy

            14.2.7.4. Recent Developments

        14.2.8. BioGenex

            14.2.8.1. Overview

            14.2.8.2. Financials

            14.2.8.3. Strategy

            14.2.8.4. Recent Developments

        14.2.9. Cell Signaling Technology, Inc.

            14.2.9.1. Overview

            14.2.9.2. Financials

            14.2.9.3. Strategy

            14.2.9.4. Recent Developments

        14.2.10. Agilent Technologies, Inc.

            14.2.10.1. Overview

            14.2.10.2. Financials

            14.2.10.3. Strategy

            14.2.10.4. Recent Developments

        14.2.11. PerkinElmer Inc.

            14.2.11.1. Overview

            14.2.11.2. Financials

            14.2.11.3. Strategy

            14.2.11.4. Recent Developments

        14.2.12. Bio SB

            14.2.12.1. Overview

            14.2.12.2. Financials

            14.2.12.3. Strategy

            14.2.12.4. Recent Developments

        14.2.13. Cancer Genetics Inc.

            14.2.13.1. Overview

            14.2.13.2. Financials

            14.2.13.3. Strategy

            14.2.13.4. Recent Developments

        14.2.14. Danaher Corporation

            14.2.14.1. Overview

            14.2.14.2. Financials

            14.2.14.3. Strategy

            14.2.14.4. Recent Developments

        14.2.15. ROSETTA GENOMICS

            14.2.15.1. Overview

            14.2.15.2. Financials

            14.2.15.3. Strategy

            14.2.15.4. Recent Developments

        14.2.16. Nanoprobes, Inc.,

            14.2.16.1. Overview

            14.2.16.2. Financials

            14.2.16.3. Strategy

            14.2.16.4. Recent Developments

        14.2.17. Creative-Biolabs

            14.2.17.1. Overview

            14.2.17.2. Financials

            14.2.17.3. Strategy

            14.2.17.4. Recent Developments

        14.2.18. Enzo Life Sciences, Inc

            14.2.18.1. Overview

            14.2.18.2. Financials

            14.2.18.3. Strategy

            14.2.18.4. Recent Developments

        14.2.19. Sigma-Aldrich Co. LLC

            14.2.19.1. Overview

            14.2.19.2. Financials

            14.2.19.3. Strategy

            14.2.19.4. Recent Developments

15. Assumptions and Acronyms Used

16. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 2: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

Table 3: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 4: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 5: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 6: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 7: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 8: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 9: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 10: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 11: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 12: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Regional market revenue growth for both tests is expected to remain sTable over the forecast period, given rising demand

Table 13: Japan Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 14: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 15: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Cancer Tissue Diagnostics Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 2: Global Cancer Tissue Diagnostics Market Absolute $ Opportunity, 2022-2032

Figure 3: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 4: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 5: Global Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 6: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 7: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 8: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 9: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Region, 2022 & 2032

Figure 10: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Region, 2022-2032

Figure 11: North America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 12: Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 13: Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 14: Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 15: APEJ Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 16: Japan Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 17: MEA Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 18: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By Region, 2022-2032

Figure 19: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022, 2032

Figure 20: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 21: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 22: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 23: North America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 24: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 25: U.S. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 26: Canada Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 27: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By Country, 2022-2032

Figure 28: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 29: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 30: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022 & 2032

Figure 31: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 32: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 33: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 34: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 35: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 36: Brazil Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 37: Mexico Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 38: Rest of Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 39: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2022-2032

Figure 40: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 41: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 42: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022 & 2032

Figure 43: Western Europe Cancer Tissue Diagnostics Market

Figure 44: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 45: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 46: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 47: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 48: Germany Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 49: Italy Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 50: France Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 51: U.K. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 52: Spain Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 53: Rest Of Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 54: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2022-2032

Figure 55: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 56: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 57: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022 & 2032

Figure 58: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 59: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 60: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 61: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 62: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 63: Poland Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 64: Russia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 65: Rest of Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 66: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2022-2032

Figure 67: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 68: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 69: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022 & 2032

Figure 70: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 71: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 72: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 73: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 74: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 75: China Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 76: India Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 77: ASEAN Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 78: Australia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 79: Rest of APEJ Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 80: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2022-2032

Figure 81: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 82: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 83: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 84: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 85: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 86: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 87: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 88: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 89: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2022, 2032

Figure 90: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 91: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 92: Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 93: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 94: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 95: GCC Countries Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 96: South Africa Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 97: Rest of MEA Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 98: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2022-2032

Figure 99: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 100: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Lung Cancer Therapeutics Market

Published : February 2022

Healthcare

Tissue Diagnostics Market

Published : July 2020

Healthcare

Lung Cancer Surgery Market

Published : January 2022

Google translate

Cancer Tissue Diagnostics Market